Hot Flashes, New Rules: What Doctors Now Recommend for Menopause Treatment

Millions of women suffer hot flashes, night sweats and insomnia in silence — partly because treatment advice has been stuck in the shadow of a scare from 2002. This week, America's leading obstetricians and gynecologists rewrote the rulebook for the first time in more than a decade. Here is what the new guidelines actually say.

What's new: the first update since 2014

The American College of Obstetricians and Gynecologists (ACOG) released its first updated guidance on menopause symptoms since 2014. The headline change: hormone replacement therapy now carries the group's strongest possible recommendation for hot flashes, night sweats and the sleep lost to them — for women without a medical reason to avoid hormones. The guideline also endorses certain antidepressants, nonhormonal medicines and other treatments for symptoms like mood swings and insomnia, and stresses an individualized approach built around each patient's symptoms, age and history.

Why hormone therapy got its top grade

Estrogen is the core of the treatment. Women who still have a uterus also take a progestogen to protect the uterine lining; women who have had a hysterectomy can usually take estrogen alone. Notably, estrogen delivered through the skin ranked as the most effective option for reducing how often hot flashes occur. The evidence now supports starting before age 60 or within 10 years of the final menstrual period — women in that window showed lower heart disease risk in the studies the guideline reviewed. There is no automatic stop date; when and how to taper off is a shared decision with your clinician, based on risks at that point.

The 2002 shadow — and what replaced it

To understand why this matters, go back to 2002, when the Women's Health Initiative suggested hormone therapy raised the risk of heart disease, breast cancer, stroke and blood clots. Use of hormones collapsed — and never fully recovered. But researchers later found that the study's participants were mostly 60 or older, making it hard to generalize to younger menopausal women. Since then, more and better-quality studies have rebuilt the evidence base. In 2025, the FDA removed the old boxed warnings for heart disease, breast cancer and probable dementia from menopausal hormone therapy labeling — a change the new guideline explicitly highlights.

What to ask your doctor

The guidance also flags one safety rule worth knowing: unexpected bleeding after starting hormone therapy should always be checked. And hormone therapy is not the only path — the new guidelines give doctors a broader toolkit of non-hormonal options for women who cannot or prefer not to use hormones. The overall message is a shift from fear to informed choice: the safety of hormone therapy is now, in the guideline authors' word, well-established.

For more on women's health research, read our coverage of the study on autoimmune misdiagnosis in women.

This article is general information only and is not medical advice.

Follow Global Insight for more health explainers grounded in real evidence.